Mode
Text Size
Log in / Sign up
N/A Completed N=48 Treatment

A Study of BiZact™ on Adults Undergoing Tonsillectomy

Source: ClinicalTrials.gov NCT02876575 ↗
Enrolled (actual)
48
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcomePrimary: Pain Assessment Using a Visual Analog Scale (VAS) — 5.4 units on a scale

Summary

The purpose of this study is to assess the severity of post-operative pain following the use of the BiZact™ device in adult (≥22 years of age in United States and ≥18 years of age in Europe) tonsillectomy procedures.

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Assessment Using a Visual Analog Scale (VAS)
1.2
SECONDARY
Time to Normal Diet Following the Use of the BiZact™ Device in Adult (≥22 Years of Age in United States and ≥18 Years of Age in Europe) Tonsillectomy Procedures
12.3
SECONDARY
Time to Normal Activity Following the Use of the BiZact™ Device in Adult (≥22 Years of Age in United States and ≥18 Years of Age in Europe) Tonsillectomy Procedures
12.4

Eligibility Criteria

Inclusion Criteria

  • Adults (male or female) ≥22 in United States and ≥18 years of age in Europe years of age
  • Scheduled to undergo tonsillectomy
  • Signed informed consent by subject

Exclusion Criteria

  • Subjects undergoing:
  • Simultaneous adenoidectomy
  • Tonsillectomy as a result of cancer
  • Unilateral tonsillectomy
  • Current participation in other clinical trials
  • Subjects with:
  • Current tobacco use
  • Known bleeding disorders
  • History of peritonsillar abscess
  • Craniofacial disorders
  • Down syndrome (Trisomy 21)
  • Cerebral palsy
  • Major heart disease (including but not limited to; right-sided heart failure, left-sided heart failure, congestive heart failure, coronary artery disease, arrhythmias, chronic heart failure, acute heart failure, etc.)
  • Subjects unable to comply with the required study follow-up visits
  • Pregnancy
  • The subject has comorbidities which, in the opinion of the investigator, will not be appropriate for the study or the subject has an estimated life expectancy of less than 6 months
  • Any subject who is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity)
  • The subject has participated in any drug or device research study within 30 days of enrollment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02876575). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search